Fig 1.
Global strategy of the analysis illustrating the times of sample collection, the parameters collected and the three main objectives of the study.
Table 1.
Characteristics of patients at baseline (one month after the randomisation visit).
Data from the entire cohort [6] are provided to confirm the representativeness of the population selected for the present study. Probability values correspond to the comparisons between Group O and Group P in this present study.
Fig 2.
Multivariate model from blood metabolome of ALS patients at V1, A) Score scatter plot from OPLS-DA model discriminating patients in Group P (black) from patients in Group O (red), B) Loading scatter plot from OPLS-DA model showing the best discriminating metabolites. The position of the metabolites in the loading plot characterises the subjects represented in the score plot; variables near each other are positively correlated; variables opposite to each other are negatively correlated. Amino acids are represented in blue, complex lipids in orange, fatty acids in yellow and other molecules in green.
Fig 3.
Venn diagram representing the 15 best discriminating metabolites between patients in Group P and patients in Group O at V1, V12 and over one year (V12-V1) in OPLS-DA models built from blood metabolomic profiles.
Fig 4.
Venn diagram representing the 15 most discriminating metabolites in PLS-DA models which are associated with disease evolution (variation of ALSFRS-r, BMI, MMT, SVC over 1 year) in patients in Group P.
Fig 5.
Venn diagram showing the 15 most discriminating metabolites in PLS-DA models which are associated with disease evolution (variation of ALSFRS-r, BMI, MMT, SVC over 1 year) in patients in Group O.